Table 3.

Cox regression analyses of time to mCRPC

	Univariate analysis		Multivariate analysis
Time to mCRPC	Hazard ratio (95% CI)	p value	Hazard ratio (95% CI)	p value
Model 1
Any gDDRm	2.37 (1.48–3.80)	<.001	1.98 (1.22–3.23)	.006
Treatment (combination therapy vs. ADT alone)	1.00 (0.62–1.63)	.9	0.86 (0.51–1.43)	.6
Age of onset, yr	0.99 (0.96–1.01)	.4	0.99 (0.97–1.02)	.5
Baseline PSA (log), ng/mL	1.38 (0.99–1.91)	.058	1.14 (0.79–1.64)	.5
Gleason grade group (4–5 vs. 1–3)	1.63 (0.84–3.16)	.15	1.85 (0.95–3.61)	.070
High‐volume disease (present vs. absent)	1.86 (1.17–2.94)	.008	1.74 (1.07–2.82)	.024
PSA nadir within the first 7 mo (>4 vs. ≤4), ng/mL	1.36 (0.91–2.04)	.13	1.57 (1.02–2.41)	.042
Model 2
mBRCA2 mutation	3.73 (2.12–6.58)	<.001	3.14 (1.76–5.60)	<.001
Treatment (combination therapy vs. ADT alone)	0.94 (0.57–1.55)	.8	0.67 (0.39–1.14)	.14
Age of onset, yr	0.99 (0.97–1.01)	.4	0.99 (0.97–1.02)	.8
Baseline PSA (log), ng/mL	1.32 (0.94–1.86)	.11	1.05 (0.72–1.53)	.8
Gleason grade group (4–5 vs. 1–3)	1.48 (0.74–2.98)	.3	1.25 (0.61–2.55)	.5
High‐volume disease (present vs absent)	1.93 (1.20–3.11)	.007	1.97 (1.21–3.22)	.007
PSA nadir within the first 7 mo (>4 vs ≤4), ng/mL	1.42 (0.93–2.16)	.10	1.55 (0.98–2.44)	.059

Model 1 evaluated the effect of any gDDRm versus wild‐type. Model 2 evaluated the effect of BRCA2 mutation versus wild‐type.

High‐volume disease was defined as the presence of visceral metastases or ≥ 4 bone lesions with at least one outside of the vertebral column and pelvis according to the CHAARTED trial.

Abbreviations: ADT, androgen deprivation therapy; CI, confidence interval; gDDRm, germline DNA repair gene mutations; PSA, prostate‐specific antigen.